Istari Oncology

[On Demand]
Istari Oncology, Inc. is a US-based, clinical-stage biotechnology company focused on novel immunotherapy platforms for the treatment of solid tumors.

Istari Oncology boasts an experienced leadership team from biopharma giants like Novartis, GSK and Merck and backed by a vetted Board of Directors and renowned venture capital partners.

Istari’s lead asset is PVSRIPO - a novel, investigational viral immunotherapy based on the live attenuated Sabin type 1 poliovirus vaccine, which has been genetically modified for safety. We believe PVSRIPO to be the “best in class” intratumoral therapy and ideal combination partner for PD-1/L1 inhibitors, thanks to its ability to activate innate and adaptive immunity to facilitate a systemic, polyfunctional antitumor CD8+ T cell response.

Istari’s robust and expanding clinical trial program is investigating PVSRIPO in combination with PD-1/L1 inhibitors across a range of solid tumors at many of the leading cancer institutions in the US.
Company Type:
Privately Funded Company
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Medical Officer
Istari Oncology